retatrutide peptide clinical trial results Lilly orforglipron oral GLP-1 phase 3 weight loss Lilly's 'triple G' agonist triumphs

Just send a message

The findings raise concern about optic nerve vulnerability Although the report was not designed to demonstrate how the drugs may be associated with the damage, the authors suggested the optic nerve may be particularly sensitive to changes in blood flow or pressure related to GLP-1 drugs

This flexibility accommodates patients' daily routines and reduces the inconvenience of maintaining strict refrigeration at all times

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention